Potential of the trifunctional bispecific antibody surek depends on dendritic cells: rationale for a new approach of tumor immunotherapy

Mol Med. 2013 Apr 30;19(1):54-61. doi: 10.2119/molmed.2012.00140.


Trifunctional bispecific antibodies (trAbs) used in tumor immunotherapy have the unique ability to recruit T cells toward antigens on the tumor cell surface and, moreover, to activate accessory cells through their immunoglobulin Fc region interacting with activating Fcγ receptors. This scenario gives rise to additional costimulatory signals required for T cell-mediated tumor cell destruction and induction of an immunologic memory. Here we show in an in vitro system that most effective trAb-dependent T-cell activation and tumor cell elimination are achieved in the presence of dendritic cells (DCs). On the basis of these findings, we devise a novel approach of cancer immunotherapy that combines the specific advantages of trAbs with those of DC-based vaccination. Simultaneous delivery of trAbs and in vitro differentiated DCs resulted in a markedly improved tumor rejection in a murine melanoma model compared with monotherapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Antibodies, Bispecific / pharmacology*
  • Cell Line, Tumor
  • Cells, Cultured
  • Coculture Techniques
  • Dendritic Cells / immunology*
  • Female
  • Immunotherapy*
  • Melanoma / immunology
  • Melanoma / therapy*
  • Mice
  • Mice, Inbred C57BL
  • T-Lymphocytes / immunology*


  • Antibodies, Bispecific